ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES?
https://doi.org/10.14412/1995-4484-2020-225-231
Abstract
The paper describes a clinical case of a male patient with verified systemic lupus erythematosus (SLE) and manifestations of lupus nephritis with impaired renal nitrogen excretory and filtering functions, central nervous system lesion (focal epilepsy), hematological (hemolytic anemia) and immunological (anti-double-stranded DNA antibodies, hypocomplementemia, positive antinuclear factor) disorders, and antiphospholipid syndrome (APS). The disease originated from APS: thrombosis in the radial and ulnar arteries. Subsequently, organ damages were considered as a consequence of thrombotic microangiopathy, which can occur with both APS and SLE.
Keywords
antiphospholipid syndrome,
systemic lupus erythematosus,
thrombotic microangiopathy,
vasculopathy,
thrombophilia,
clinical case
Supporting agencies: The investigation was conducted as part of the topic of the V.A. Nasonova Research Institute of Rheumatology “The development of methods for personalized treatment of rheumatic diseases with comorbid pathology” (АААА-А19-119021190151-3).
About the Authors
F. A. Cheldieva
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
22/1, Barrikadnaya St., Build. 1, Moscow, 125993
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
22/1, Barrikadnaya St., Build. 1, Moscow, 125993
S. G. Radenska-Lopovok
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
22/1, Barrikadnaya St., Build. 1, Moscow, 125993
38, Trubetskaya St., Build. 2, Moscow 119991
Yu. O. Korsakova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
22/1, Barrikadnaya St., Build. 1, Moscow, 125993
References
1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x
2. Nasonov EL. Antifosfolipidnyi sindrom. Monografiya [Antiphospholipid syndrome. Monograph]. Moscow: Litterra; 2004. P. 36 (In Russ.)
3. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33. doi: 10.1136/ard.2006.067033
4. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes («MAPS»): semantic or antisemantic? Autoimmun Rev. 2008;7(3):164-7. doi: 10.1016/j.autrev.2007.11.009
5. Musa MO, Nounou R, Sahovic E, et al. Fulminant thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus and phospholipid autoantibodies. Eur J Haematol. 2000;64:433-5. doi: 10.1034/j.1600-0609.2000.9l125.x
6. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. doi: 10.1002/art.10187
7. Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am. 1990;4:219-41. doi: 10.1016/S0889-8588(18)30514-8
8. Saha M, McDaniel JK, Zhang L. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost. 2017;15:1889-900. doi: 10.1111/jth.13764
9. Camous L, Veyradier A, Darmon M, et al. Macrovascular thrombosis in critically ill patients with thrombotic microangiopathies. Intern Emerg Med. 2014 Apr;9(3):267-72. doi: 10.1007/s11739-012-0851-4. Epub 2012 Oct 7.
10. Symmers W. Thrombotic microangiopathic haemolitic anaemia (thrombotic microangiopathy). BMJ. 1952;ii:897-903. doi: 10.1136/bmj.2.4790.897
11. Makatsariya AD, Brener B, Bitsadze VO, Akin'shina SV. Thrombotic microangiopathy. In: Sistemnyi venoznyi i arterial'nyi tromboembolizm v akushersko-ginekologicheskoi praktike [Systemic venous and arterial thromboembolism in obstetric and gynecological practice]. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016. P. 853-77 (In Russ.)
12. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992 Sep;19(9):1474-8.
13. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8.
14. Glueck HI, Kant KS, Weiss MA, et al. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med. 1985 Aug;145(8):1389-95. doi: 10.1001/archinte.145.8.1389
15. Kant KS, Pollak VE, Weiss MA, et al. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore). 1981 Mar;60(2):71-86. doi: 10.1097/00005792-198103000-00001
16. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990 May;112(9):682-8. doi: 10.7326/0003-4819-112-9-682
17. Farrugia E, Torres VE, Gastineau D, et al. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis. 1992 Nov;20(5):463-71. doi: 10.1016/S0272-6386(12)70258-5
18. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int. 1991 Jun;39(6):1225-31. doi: 10.1038/ki.1991.155
19. Tsai HM. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2004 Oct;30(5):549-57. doi: 10.1055/s-2004-835675
20. Babar F, Cohen SD. Thrombotic microangiopathies with rheumatologic involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010. Epub 2018 Sep 7.
21. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008 Oct;23(10):1761-7. doi: 10.1007/s00467-007-0616-x
22. Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012 Jul;27(7):2673-85. doi: 10.1093/ndt/gfs279
23. Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. Arthritis Rheum. 2002;46(4):1019-27.
24. Arachchillage DRJ, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2014;113:13-9. doi: 10.1160/TH14-05-0416
25. Silvarino R, Sant F, Espinosa G, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20:721-9. doi: 10.1177/0961203310397410
26. Amigo MC, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol. 1992;19:1181-5.
27. Turrent-Carriles A, Herrera-Felix JP, Amigo M-C. Renal involvement in antiphospholipid syndrome. Front Immunol. 2018;1(9):1008. doi: 10.3389/fimmu.2018.01008
28. Praprotnik S, Ferluga D, Vizjak A. Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009 Jun;36(2-3):109-25. doi: 10.1007/s12016-008-8104-z
29. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-50. doi: 10.1097/01.ASN.0000108969.21691.5D
30. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000 Jan;79(1):57-68. doi: 10.1097/00005792-200001000-00006
31. Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006 Nov 13;166(20):2278-84. doi: 10.1001/archinte.166.20.2278
32. Murphy J, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J. 1989 Jul;62(1):61-4. doi: 10.1136/hrt.62.1.61
33. Brown JH, Doherty CC, Allen DC, et al. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J (Clin Res Ed). 1988 May 28;296(6635):1505. doi: 10.1136/bmj.296.6635.1505
34. Kaplan SD, Chartash EK, Pizzarello RA, et al. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J. 1992 Nov;124(5):1331-8. doi: 10.1016/0002-8703(92)90420-z
35. Reshetnyak TM. Treatment of antiphospholipid syndrome: modern standards. Tromboz, Gemostaz i Reologiya. 2016;1(65):11-20. doi: 10,25555/THR/2017/3/0790 (In Russ.)
Review
For citations:
Cheldieva F.A., Reshetnyak T.M., Radenska-Lopovok S.G., Korsakova Yu.O., Lila A.M. ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES? Rheumatology Science and Practice. 2020;58(2):225-231. (In Russ.) https://doi.org/10.14412/1995-4484-2020-225-231
Views:
2990
Email this article 